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PREFACE 
As a first year medical student I naively wondered, what is the 
relationship between allergy and cancer? After all, I reasoned with 
a limitless lack of sophistication, the immune system must have some- 
thing to do with both diseases. When I posed this question two years 
later to John Dwyer, my adviser, I received the answer that stimulated 
much of Ttfhat I now report. His reply was, "The question has merit. Go 
to the library. Find out what you can. Report back to me." Duti¬ 
fully I began to search the journals trying to resolve such broad 
issues as do atopies develop cancer as often as normals?; could those 
with allergy have a genetic selective advantage in immunosurveillanee, 
the rejection of malignant clones before their clinical presentation?; 
what is the role of IgE, that immunoglobulin class primarily respon¬ 
sible for allergy, in responding to neoplasia? Armed with questions 
like these, a pattern was established, I would read and report; John 
Dwyer would listen, question, suggest. Slowly we elaborated projects to 
resolve specific issues. 
The laboratory in which these experiments were undertaken possesses 
many skills in immunological research. In particular, the lab is expert 
in assessing T and B cell function and investigating cutaneous basophil 
hypersensitivity responses. The laboratory's lack of prior experience 
with research on IgE provided me with great latitude in experimentation, 
but this also meant that a substantial amount of time had to be devoted 
to basics before the proposed tumor work could be successfully engineer¬ 
ed 
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The thesis then contains three natural divisions. Part I stems 
directly from that first naive question; it is a review of the litera¬ 
ture regarding the relation between IgE and neoplasia. Part II de¬ 
rives from the need to understand some basic properties of IgE, It 
describes studies that have no direct relation to tumor immunology but 
includes such fundamental topics as the assay of IgE and the ©ntogene- 
tics of IgE production. Finally, Part III concerns specifically the 
relation between IgE and tumors. 
In many ways, this work is unfinished. This is not the study's 
defect, but rather its virtue. The topics explored were constantly 
demanding clarification of results, suggesting further study, and re¬ 
quiring refinement of techniques. This thesis project resembles the 
process of education by representing the construction of a starting 
gate from which to conduct a marathon, not a dash. While the finish 
line has not yet been reached, many hurdles have been cleared and most 
important, a direction in which the runners can head has been established. 
The naive medical student has changed little since his initial ques¬ 
tion, but he has discovered that even questions asked out of ignorance 
may merit exploration. 

PART I: A Review of the literature 
Few topics in medicine are currently generating as much interest 
as the relationship between the immune system and malignancy. Recent 
reviews-®-^,208,245 have covered such relevant issues as blocking anti¬ 
bodies, cell-mediated immunity, tumor associated antigens, immunosurve¬ 
illance, immunodeficiency, and immunotherapy. With such a plethora of 
interests demonstrating a definite relationship between the immune system 
and cancer, not surprisingly all reviews omit any mention of the ambig¬ 
uous role that immunoglobulin S or IgE plays in response to neoplasia. 
Yet much suggests the importance of just this subject. 
Background 
Basic facts about IgE, which is sometimes called reaginic, skin- 
sensitizing, or homocytotropic antibody, have been reviewed thoroughly 
and the reader is referred elsewhere^* ^2 for detailed information. In 
brief, as recently as ten years ago, the antibody responsible for immed¬ 
iate wheal and flare skin reactions was thought to be a subclass of IgA. 
Then, in 1966, careful work by K. Ishizaka and his colleagues showed 
reaginic antibody to be a unique class of immunoglobulin,^ ^ This was 
confirmed shortly thereafter by the discovery of an IgE myeloma,and 
the demonstration that antisera to the myeloma protein could absorb re¬ 
aginic activity from serum,Several parasitic infections^71*196,210 
and atopic diseases^® including asthma,1°3»121 allergic rhinitis,^14 
and atopic eczema^*® ^ are often characterized by elevated levels of IgE. 
Reagin is thought to be primarily responsible for immediate type hyper- 
senstivity responses such as anaphylaxis. Some evidence suggests that 
IgE might have a role in such diverse entities as Graves' disease^39 
and the nephrotic syndrome.70,133 IgE is present in the serum in ex- 
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tremely low concentrations,^®^ nanograms per milliliter, and is also 
tissue bound to basophils and mast cells„^5@ 99 An IgE-antigen reac¬ 
tion can trigger the release of potent mediators including hista¬ 
mine, ^55 siow reacting substance of anaphylaxis(SR3-A)255( and 
eosinophilic chemotactic factor.^-® 
Intuitive Arguments 
The idea that individuals x-dth atopy may have a significantly 
lower incidence of malignancy has occurred to many investigators. One 
intuitive argument could be stated as a syllogism; Cancer begins as a 
failure of the immune system, an immunodeficiency; in allergy, the im¬ 
mune system is over-active or hypersensitive; therefore, perhaps the 
immunosurveillance system of an atopic is more likely to reject a clone 
of malignant cells before a cancer is clinically apparent. 
In rejecting this logic, a response might stress that the patho¬ 
genesis of atopy should not be considered merely as an excess of IgE or 
an exaggeration of the normal immune response. First, no study has 
shown that all those with asthma, allergic rhinitis, or atopic eczema, 
have increased total IgE; roughly thirty to sixty per cent of atopies 
can be characterized as such,»105»106,121,134,210 although an eleva¬ 
tion of antigen-specific IgE antibodies does correlate more closely 
with the incidence of allergic symptoms,-^4 Second, atopies clearly 
have other immune aberrations. Recent studies have suggested that T- 
cell function, both as tested in vivo by delayed hypersensitivity skin 
testing and in vitro as tested by mitogen stimulation, is depressed in 
atopic disease,*^5,138,155,262 although studies in our lab and else¬ 
where have not confirmed these findings,38,52,55»65 s©rafini has shown 

-5- 
that allergic patients have markedly increased autoantibodies of the 
203 thyro-gastric group. Evidence suggests that reaginie antibodies 
are qualitatively and not just quantitatively abnormal in atopic per- 
sons,~^ Some have contended that the primary / immune disturbance in 
allergic individuals is actually a transient IgA deficiency, not an 
IgE elevation. c And numerous excellent studies in animals are 
demonstrating the role of the T-cell in regulating IgE.’ 9»81,174-176, 
222-225 
A second intuitive argument considers genetic laws. The inci¬ 
dence of atopy may be as high as twenty-four percent of the popula- 
207 tion. Allergy has long been recognized as familial'J and now 
. , . . , , 20,21,130,150 , 151,229,230 
evidence has mounted that both in man and mouse 
IgE levels are genetically determined. One would hope to find then 
some selective advantage in being allergic, but none has been proven. 
While IgE levels are clearly elevated in many parasitic infestations, 
only debatable arguments claim any benefit from this elevation.^4’^^* 
125,126 gome have suggested that IgE protects against respiratory in- 
fections pf IgA is absent'* ' and that possibly the IgE system serves 
as a warning about pollutants, but equally good data indicate that IgE 
Iga 
in the presence of IgA deficiency predisposes to pulmonary disease. 
Individuals apparently perfectly normal have been shown to be IgE de¬ 
ficient. ^2,184 Although without substantiation, the argument is tan¬ 
talizing, If a quarter of the population has a genetic defect, namely 
the tendency to develop allergic symptoms, then there must be an unre¬ 
cognized selective advantage somehow involved -with this '’defect". 
Hoping to show that this selective advantage involves the response 
to tumors, at least nine separate investigations have been published on 
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the incidence of allergy or atopy in patients with malignan¬ 
cies.56,63,66,139,141,156,159,204,228 The first such study139 pub¬ 
lished in 1953 actually concluded that patients with cancer, mainly 
carcinoma of the cervix in this report, were far more likely to have 
allergies (27$) as compared to controls (11$), The study has several 
major defects, however, including the authors' effort to prove an 
hypothesis that they had formulated before the investigation, thus 
biasing their inquiries, and the lack of age or sex matched controls. 
Of the eight subsequent studies along this line, five concluded 
that patients with malignancy had a significantly decreased incidence 
of atopy, while three studies disclosed no difference between normals 
and patients with cancer. These studies all differ markedly in such 
essential parameters as the definition of allergy or atopy, the care 
in matching controls, the range in types of malignancy studied, and 
the size of the population. Some of the findings of all nine studies 
are summarized in Table I. The publication of so many reports has 
served to confuse rather than clarify, as evidence accumulates that 
atopy is both relevant and irrelevant to the incidence of carcinoma. 
Total Serum IgE and Malignancy 
With the ability to measure serum IgE, however, it seemed that 
the controversy could be settled more definitively by simple assaying 
IgE in the serum of normals and those with cancer. Indeed, at least 
four groups of investigators have tried this approach, but here, too, 
opinion is not unanimous, 
13 Augustin and Chandradasa were first to publish their results on 
serum IgE in patients with neoplasia in 1971. Using a radial immuno¬ 
diffusion technique to measure IgE, they found that the mean serum value 
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of this immunoglobulin was depressed in 65 patients with cancer as 
compared to 50 controls. But IgE levels were also decreased in 48 
hospitalized surgical patients. No statistically significant differ¬ 
ence was found between the cancer group and the surgery controls or 
between the surgery patients and the normals.Still» this report is 
often cited as one that shows decreased IgE in patients with cancer. 
102 
In 1972, Jacobs et at. measured IgE levels in 50 patients with 
allergy, 100 normals, 200 with untreated advanced carcinoma, and 200 
with carcinoma undergoing chemotherapy with cyclophosphamide. Both a 
radial immunodiffusion and solid phase radio-immunoassay (RIA) were 
used. Most of the tumors were bronchogenic carcinomas. While the major¬ 
ity of cancer paitents had low levels of IgE, many of the untreated sub¬ 
jects had falsely elevated serum levels as shown by the high levels by 
RIA and undetectable values by immunodiffusion. This false elevation may 
be due to an auto-antibody which is also present in normal sera and is of 
l60 
unknown significance. Other authors have also found autoantibodies 
1 242 
against IgE in normal serum. * 
Q 
Arbesman et al,7 utilised their own radio-radial Immunodiffusion 
technique to evaluate IgE levels in patients with various diseases includ¬ 
ing malignancy. Of 282 patients with cancers, 32 had what the authors 
considered to be an elevated level, greater than 300 units per milliliter, 
like the two previous studies, they conclude that IgE seems to be de¬ 
creased with malignancy, but no statistically significant difference was 
proven between the cancer group and the blood bank donor controls. 
The study of Waldmann et al. J was most recently published. The 
main advantage of their work is the use of a double antibody radio- 
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immunoassay^2 which is particularly sensitive when low values of IgE 
or non-specific interference with the assay are possibilities. ~J 
Their data is also submitted to statistical analysis and includes only 
immunoglobulin levels of patients on first admission to the hospital, 
thereby eliminating the complication of therapy possibly altering IgE 
levels. Studying 331 cases of neoplasia, the authors conclude that 
IgE levels are generally normal with cancer. However, patients with 
B-cell malignancies such as multiple myeloma and chronic lymphatic 
leukemia do have depressed levels of serum IgE just as they have de- 
231 
pression of other immunoglobulin classes. This is often explained 
as a crowding out of the normal B-cell or antibody-producing precursors 
by neoplastic cells. Finally, and most intriguingly, patients with 
Hodgkin’s disease have clearly elevated levels of IgE which the authors 
9 
suggest may be due to a depression of T-cell function, Arbesman et al. 
had likewise shown elevated levels correlating with the stag© of the 
disease. 
Numerous investigators are actively exajdh&fgthe role of the T-cell 
in regulating IgE responses. Host manipulations that destroy T-cell 
function including thymectomy,^5 irradiation,-^,1?5 and treatment with 
anti-lymphocyte serum seem to favor IgE production. One group has 
isolated a soluble factor from thymocytes that can suppress an IgE res- 
223 
ponse. Since Hodgkin’s disease has decreased T-cell function with the 
incidence of anergy correlating with the stag© of the disease, a possible 
cause of the elevated IgE especially in stag© III and IV disease, becomes 
apparent, 
Although the association may just be coincidental, Hodgkin's dis¬ 
ease is associated with two phenomena also related to IgE, The neph- 
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rotic syndrome not infrequently accompanies Hodgkin's disease, and as 
IgE may be a causative factor in some forms of nephrosis, at least one 
physician has speculated that the nephrotic syndrome in Hodgkin's 
might be related to an IgE response.^ Second, fifteen to twenty per¬ 
cent of Hodgkin's disease patients have eosinophilia,^ some to a very 
marked degree,and the speculative possibility exists that this 
is related to reagin, 
Hodgkin's Disease in an Animal Model 
The SJL mouse strain develops a spontaneous neoplasm often consi- 
3 dered to be an animal model of Hodgkin's disease. Paradoxically, in 
published reports so far, this mouse has been shown to be a very poor 
producer of reagin^^ and it has even been noted, that its failure to 
make IgE might relate to its tendency to develop tumors,Despite 
its seeming inability to produce IgE, the SJL mouse has been reported 
227 
to be among the most susceptible mice to anaphylaxis, although mice 
have reaginic antibody other than IgE and non-reaginic factors may also 
mediate anaphylaxis, 
82 
Haran-Ghera et at, have made a thorough study of the SJL mouse 
in order to consider the possibilitycf predicting by immune parameters 
which individuals irould develop the spontaneous reticulum cell neoplasm 
resembling Hodgkin's. Examining such criteria as presence of antinuclear 
antibodies, antibody response to sheep red blood cells, and rejection of 
skin grafts, they were unable to distinguish those animals that were to 
235 
develop tumors, Warren has shown that SJL mice make a poor immune 
response to schistosoma mansoni eggs when compared to DBA/2 controls. 
His criterion for response was the size of granulomata in the lung six- 
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teen days after the eggs were given intravenously, As many believe that 
IgE is a crucial factor in responses to parasites, a poor reaginic res¬ 
ponse might account for the smaller granulma in SJLs. 
With the evidence that humans with Hodgkin's disease have increased 
IgE but that animals that supposedly develop a Hodgkin's-like tumor have 
low IgE levels, further study is needed. What, for example, are the IgE 
levels in the mouse after the onset of tumor? Could variability in mak¬ 
ing IgE have predictive value as to which animal will develop the neo¬ 
plasia? These studies would be facilitated by the ability to measure 
total serum IgE in the mouse. This can be done in the rat^2,42 thanks 
to the discovery of IgE myeloma proteins in this species,^3 but comparable 
tumors have not been described in the mouse. At present mouse IgE levels 
can be titered only in relation to a specifics anti os by the method of 
passive cutaneous anaphylaxis, (See methods in Part II.) 
Tumor-Specific IgE Responses 
Since nine studies have failed to show conclusively if atopies have 
a decreased incidence of carcinoma, and four studies on serum IgE seem 
now to point normal levels of IgE in malignancies except in Hodgkin's 
disease (for which a few authors would even question its status as a 
neoplasia)\ can IgE still be playing a significant role in response to 
neoplasia? Some experimental work published in 1958 strongly suggests 
that IgE may play a critical role in responding to some tumors, 
74 Seventeen years ago, Grace and Kondof reported on eight patients, 
give with breast cancer, two with Hodgkin's and one with a lymphoma, all 
of whom had "heat, edema, and tenderness" locally about their tumor, With 
extracts of each tumor, they produced a wheal and flare reaction within 
fifteen to twenty minutes after an intradermal injection into the patient's 
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own skin, an immediate hypersensitivity response as is mediated try IgE, 
As controls, patients had no reactions to saline or normal tissue. As 
added proof, the reaction could be pqssively transferred by first in¬ 
jecting a normal volunteer with appropriate serum intraderaally and 
one day later challenging that site with solubilized tumor antigen. 
This classic Prausnitz-Kustner (P-K) reaction following a twentyfour 
hour sensitization must be mediated primarily by iggf91#186,211 as 
IgE was not known to be a distinct antibody class until 1966, the true 
significance of this report has been overlooked. The paper is usually 
cited only to show that antibodies, but not specifically reaginic anti¬ 
bodies, were made against the tumor. A P-K reaction was also demonstrated 
73 by Grace and Dao J in a patient with breast cancer and dermatomyositis, and 
later by Curtis et al. again in a paitent with dermatomyositis, though 
this patient had a primary carcinoma in the signoid colon and a metastasis 
in the lung from which the extract was made. Grace was unable to pro¬ 
duce the reaction unless the patient had some sort of cutaneous mani¬ 
festation of his malignancy. 
The existence of a tumor-specific IgE responses is not at all in 
conflict with the concept that total serum IgE is normal in malignancy. 
Normal levels of IgE vary widely. For example, the lower limit of normal 
was one hundred and thirty times less than the upper limit of normal in 
72 
one study. Obviously a very significant amount of tumor-specific IgE 
could be produced and total serum levels of IgE might still remain within 
a normal range. 
Only in 1972 was an animal study published proving that a mouse 
16 
could produce IgE specific for a tumor, Partholomaeus and Keasz achi¬ 
eved this with the Bl6 melanoma and C57EL/6 mice and also showed that 
IgE could be produced against alloantigens in a transplant situation. 
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No data in man or animal has as yet been published to suggest if this 
IgE response is of benefit to the host. 
Some evidence in animals, however, might be related. Parasitic 
infestations have been shown, to act similarly to an adjuvant in stimu- 
lating an animal to rpoduce IgE against various antigens, Keller ©i 
al. ^ reported that mice infected with Nippostrongylus brasielensis, 
a nematode, were resistant to growth of a syngeneic mammary adenocar¬ 
cinoma, In rats, the Walker sarcoma could be inhibted or enhanced de¬ 
pending on the timing of the parasitic infection and tumor challenge. 
These authors suspected reagin but were unable to demonstrate it, 
Another study shows that mice with trichinella spiralis have a longer 
ooo 
survival and a decreased incidence of spontaneous mammary tumors,"''' 
Infections with trypanosoma cruzi may similarly affect spontaneous 
breast cancer in mice. As an adjuvant, Bordetella pertussis augments 
IgE responses greatly^' and also has value in tumor immunotherapy in 
14 137 nrp 
animal * models and possibly in man.'r Some speculate that IgE is 
14 137 
the factor responsible for prolonged survival. * For all these ob¬ 
servations, IgE, however, has not been proven to be the factor respon¬ 
sible for the tumor resistance and certainly multiple factors have been 
affected by the experimental manipulations. 
The Implications of an IgE Response? 
Some Hypotheses 
At least five distinct but possibly related, hypothetical mechanisms 
might account for the role of IgE in response to malignancy. 
The Gatekeeper Theory 
An obvious explanation for the role of IgE is that the release of 
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histamine and other vasoactive substances triggered by igE could be 
causing a vascular change that would hasten tumor expulsion or des- 
truction, As such, IgE or the mediatorsreleased from a degranulating 
basophil might not have a direct effect on the tumor but would act 
213 
as a catalyst or "gatekeeper", altering vessel permeability and 
thus, alloxtfing other mediators, immunoglobulins, or chemotactic sub- 
tances to interact with the neoplasm. Although at first not believed 
to activate complement} IgE has now been found capable of activating 
the alternate pathway?^>-^0 ^ v-pr^ue Df altering?; permeability, 
IgE is said to be responsible for a model of immune complex disease 
25 
in rabbits. ^ Perhaps the destruction of tissue in immune complex 
disease is not too dissimilar from the destruction of a malignant 
clone. 
Histamine 
A second mechanism for the role of IgE involves histamine. Bourne*^ 
and Lichtenstein^^ have elegantly reviewed the evidence that hista¬ 
mine, by stimulating cyclic AMP, can modulate immune responses, in¬ 
cluding basophil degranulation, cell-mediated immunity, antibody produc¬ 
tion, and neutrophil phagocytosis. In in vitro experiments, histamine 
retards all of these processes. If IgE can be directed specifically 
against a tumor, it would be expected that the IgE response would lib¬ 
erate histamine. Indeed, in a rat model it has been shown that after 
immunization with tumor and B. pertussis adjuvant, tumor challenge 
seven days later will release histamine from peritonei exudate cells, 
presumably via reagin.^^ 
If in vivo studies confirm the in vitro work on histamine, the 
first hypothesis might be that histamine release should potentiate 
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tumor growth by inhibiting lymphocyte mediated cytolysis. However, 
histamine seems to have so many possible roles that the inhibition of 
tumoricidal lymphocytes might be balanced by other positive factors. 
Histamine receptors have recently been shown to be of at least two 
31 
types, H-l and H-2. Conventional antihistamines compete for H-l 
receptors such as those responsible for smooth muscle contraction. 
The receptors for histamine on the basophil and the lymphocyte are of 
the H-2 type, that is blockable by the experimental pharmacologic 
agents, burinamide or metiamide. With the characterization of hista¬ 
mine receptors, work should now proceed rapidly elucidating the role 
of histamine vis a vis the immune response. 
Cutaneous Basophil Hypersensitivity 
Understanding a third possible interaction between IgE and tumor 
tissue may come with a greater knowledge of cutaneous basophil hyper- 
sensitivity (CEH).J This skin reaction to antigen is characterized by 
a delayed onset in time similar to classic delayed hypersensitivity, but 
the histology is marked by a high percentage of mast cells or basophils, 
CEH can be transferred with serum, but since heating the serum to 56°C 
12 does not destroy the capacity to transfer, IgE alone would not seem to 
be the serum factor. Still, with the surface of the basophil marked 
primarily by IgE, it is hard to believe that the basophil could be invol¬ 
ved without the principle immunoglobulin on its surface membrane somehow 
participating, possibly even in a negative sense. 
Further, in animal models CEM has clearly been demonstrated to have 
54 
a role in tumor rejection. In man the potential for CEH reactions can 
be monitored by a method called the skin window similar to delayed hyper- 
y 
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sensitivity skin testing. Antigen is placed over a skin scratch and the 
area covered by a coverslip. Periodically the cellular exudate collect¬ 
ing on the slip is examined, and the percentage of basophils counted. 
32 33 
Using this method, Elack and Leis have found that patients with 
breast cancer react to their autologous tumor with a basophil-laden 
exudate. They have found that the percentage of basophils correlates 
with the sinus histiocytosis in the regional lymph nodes at the time 
of surgery which in turn correlates with favorable prognosis. The cru¬ 
cial role of the basophil awaits fuller clarification, but surely IgE 
will be found to have a hand in its work. 
The Eosinophil 
Fourth, IgE has been closely linked with eosinophilia. Eosinophils 
are prevalent in allergies and parasitic infections, and a high peripheral 
eosinophil count is not uncommon with neoplasia.The ©©sinophil pro¬ 
duces an enzyme, arylsulfatase, that neutralizes SRS-A^^ and eosinophils 
88 1X0 
may inhibit histamine relase from basophils. Kay and Austen have 
demonstrated that IgE can cause the release of an eosinophilic chemo- 
tactic factor (EOF) and ectopic production of EOF has been shown in a case 
237 
of carcinoma. In a phenomenon termed radiation-related eosinophilia, 
patients with pelvic or abdominal carcinoma who receive supervoltage 
irradiation may develop an eosinophilia which actually correlates with 
their prognosis. The evidence is only circumstantial but it is tempting 
to speculate that radiation stimulates IgE perhaps try altering the anti¬ 
genicity of the tumor or by reducing suppressor T-cells. The increased 
IgE might cause the eosinophilia and either the IgE itself or the eosino¬ 
phil might favor the host response over the tumor.. Such reasoning is 
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plausible but highly speculative, and eosinophils, like IgE, may be 
working toward the patient's detriment rather than his health. Also, 
although only studied in four patients, total serum IgE has not been 
243 
found elevated in radiation-related eosinophilia, 
T-cell Function 
Finally, unraveling the relationship between IgE and the T-cell 
should be crucial in understanding the role of IgE in response to malig¬ 
nancy, Generally the T-cell is thought to be primarily responsible for 
cell-mediated immune responses that can aid the host by destroying tumor 
cells, while a humoral or E-cell response to a tumor can have a variable 
prognostic effect and may account for enhancement of tumor growth via 
blocking antibodies. 
Besides Hodgkin's disease, other illnesses with decreased T-cell 
function may have elevated IgE. In infectious mononucleosis, which is 
frequently characterized by anergy,-^ jgg may be transiently elevated 
In sarcoidosis, which is known to be associated with frequent anergy, 
Gentian investigators found IgE higher than in normal and tuberculous 
256 
controls. And in atopy, as previously alluded to, while most think of 
the primary immune dysfunction as increased IgE, several have found de¬ 
creased T-cell function. 
If decreased T-cell function is the primary defect causing elevated 
IgE, several paradoxes arise. First, besides being responsible for 
225 
suppressing IgE, the T-cell bears a factor that enhances IgE product!on, 
so one must posit that this function is intact while the suppressive func¬ 
tion is abrogated. Second, many diseases can be shown to have diminished 
T-cell function, including commonly most malignancies Why should 
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no t any tumor with depressed cell-mediated immunity have increased IgE? 
Third, how can measles vaccine simultaneously suppress both atopic sym- 
?2 65 
toms and T-cell function. 
Possibly IgE accounts for negative feedback to the T-cell. Acting 
via histamine or other mediators, it may be IgE capable of suppressing 
the T-cell as well as the T-cell capable of suppressing IgE, 
Conclusions 
At present, the relationship between IgE and other functions of 
the immune system is confusing. No unifying hypothesis has been able 
to relate IgE, the T-cell, CBH, histamine, and the eosinophil. Consider 
these puzzles. 
7,184 
Many patients with ataxia-telangiectasia have absent IgE and 
233 
this disease has a high rate of lymphoma at very young ages. On the 
other hand, some of the highest IgE levels have been recorded for patient's 
with Wiskott-Aldrich syndrome " J and they, too, develop neoplasia early 
in life.'^ If IgE abets a host response toward the tumor, why is T-cell 
function supposedly depressed in atopic eczema and why does histamine turn 
off tumor cell lysis? Are atopies more likelsr than others to produce an 
IgE response toward, a tumor? If a tumor-specific IgE response is demon¬ 
strable, what effects does it have on the prognosis? What is unique about 
Hodgkin's disease when other malignancies do not have an elevated IgE? 
An intriguing area for studying the role of IgE in response to neo¬ 
plasia might come from understanding the pathophysiology of dermatologic 
manifestations of malignancy. Although its role is uncertain, IgE has been 
, 47 
implicated in a variety of dermatidides, not just atopic eczema. In 
diseases like dermatomyositis, erythema multiforme, and pemphigoid, 
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diseases which may herald an occult malignancy, IgE may prove to be 
active in the pathogenesis of skin signs. In all the reports of either 
Grace or Curtis in which P-K reactions were demonstrated for tumor pati¬ 
ents ^ the individuals had some cutaneous manifestation of the tumor, 
Arbesman has found that IgE is commonly elevated in patients with 
8 
pemphigoid and in the fluid of its bullae,'' All of this information 
suggests that the area of IgE, carcinoma, and skin signs demands fur¬ 
ther exploration. 
While many riddles remain to be solved and questions need to be 
answered, the role of IgE in response to neoplasia is emerging as a 
provocative topic for study. 
Experimental Design and Rationale 
Desiring to clarify the relationship between IgE and neoplasia, 
we designed experiments to help resolve some of the specific issues 
raised in this literature review. Some of the studies explored directly 
the relation between IgE and a tumor; these are described in Part III, 
Other studies stemmed from a need to understand certain essentials of the 
IgE response and to perfect a serum assay. These studies were logical 
preliminaries to those described in Part III and will be considered in 
Part II, The value of undertaking these preliminary projects can perhaps 
best be demonstrated by first explaining the projects with a direct rela¬ 
tion to tumors. 
In Part III, one finds experiments toj 1) demonstrate an IgE res¬ 
ponse to tumor in animals, 2) evaluate the ability of an animal bearing 
tumor to make reagin 3) measure IgE levels in children with neoplasms 
and 4) show that humans can make a tuma^specific IgE response. 
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Demons trating IgE responses to tumor in animals was a repetition 
of the work of Bartholomaeus and Keast, but it was essential in order 
to evaluate what effect this IgE response had on the course of the 
malignancy. Evaluating the ability of an animal with tumor to make 
reagin was designed to answer whether low serum IgE in patients with 
cancer or high serum IgE in Hodgkin's disease was a cause or effect of 
the tumor. Measuring IgE levels in children with cancer was a test of 
the genetic hypothesis that atopies have a selective advantage in resis¬ 
tance to neoplasms. Finally, showing that man can make tumor-specific IgE 
was a way of duplicating the work of Grace and others without asking 
healthy volunteers to accept injections of tumor antigen as is done in 
the P-K reaction. 
With these projects in mind, x-re undertook the preliminary work des¬ 
cribed in Part II, Obviously in order to do the xrork on childhood neo¬ 
plasia, we needed to be able to measure serum IgE. So our work with a 
RIA for IgE is the first study described. Second, as we were going to 
be measuring IgE, we wished to be certain that the time of day that the 
sample was drawn was not influencing the serum level. So ruling out a 
diurnal rhythm for IgE was a necessary undertaking. Finally vie conducted 
experiments to delineate the ontogenetics of IgE production in the neonatal 
mouse, that is, the relation of IgE to IgM, G, and A. We realized that 
such a project would not directly reveal the interplay between IgE and 
tumor, but understanding the normal physiology of the IgE response -will be 
essential in understanding the factors that determine an IgE response in 
a patient -with cancer. For example, the ontogenetic model that we devised 
should allow us to study the relationship between IgE and IgA deficiency. 
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The breast can produce secretory immunoglobulin and evidence suggests 
that an IgA response may be prognostically significant in women treat- 
ed with radiation following mastectomy. On the other hand, Grace's 
work showing P-K reactions in five patients with breast cancer and 
Black's studies that show that a basophilic response is prognostically 
significant in breast carcinoma, both suggest that IgE may be impor¬ 
tant in breast tumors. Our work on ontogeny could help elucidate the 
interplay of these two secretory immunoglobulins, E and A. Just as the 
explanation for elevated IgE levels in patients with Hodgkin's disease 
has derived from studies that furthered the knowledge of the normal 
physiology of the IgE response but had no direct bearing on tumor research 
at the time they were performed, so we hoped that our work on the onto¬ 
geny of IgE would further our knowledge of the normal physiology of the 
IgE response and perhaps eventually prove relevant to tumor Immunology. 
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PART Hi Basic Studies 
(A) Radioimmunoassay 
Cne of the first problems to be solved in order to study IgE was 
the perfection of a method to assay its concentration in serum, A num¬ 
ber of techniques have been described including a solid phase radio¬ 
immunoassay (RIA) using sepharose particles (RIST) j1^5 a RIA using 
21 72 
antibody bound to bromacetyl cellulose, a double antibody RIA,' radio- 
q q 02 1 
radial diffusion, immunodiffusion, and mixed immunosorbent RIA, 
Of the two methods available commercially at the time of this writing, 
immunodiffusion can only detect elevated levels of IgE, The other, 
Pharmacia’s radioimmunosorbent test (RIST) (Phadebas Test, Phamacia, 
Piscataway, N.J.) is a radioimmunoassay essentially identical to that 
used by Johansson et at. shortly after their having described the first 
known case of an IgE myeloma. 
With practice, the Pharmacia method proved adequate for measuring 
serum IgE in the high nonaal to elevated range. However, for values 
in the range of 10 to 100 units/ml, still within normal limits, counts 
from standards with known, differing concentrations of IgE began to 
overlap and values were not reproducible. This is illustrated by the 
typical standard curve shown in Figure 1, It demonstrates graphically 
the difficulty in using this assay. Even a group that included Johansson 
21( 
himself has cautioned against the method for measuring low levels of IgE 
and a comparison study of three methods concluded that the double antibody 
RIA is the superior method for both reproducibility and assessment of low 
levels.185 
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(B) Circadian Rhythms 
Wishing to measure serum IgE, we need to explore the possibility 
that serum, levels might have a diurnal variation. While other immuno¬ 
globulins are not known to have daily fluctuations, IgE is unique in 
being present in such low concentrations, having the shortest half 
life,^4' and being tissue bound.The symptoms of allergy commonly 
vary with the time of day. And many factors possibly related to 
allergic symptomatology do have daily patterns including pollen counts, 
plasma cortisols, and circulating eosinophil counts.Conceivably, 
then, serum IgE itself might have a diurnal rhythm, perhaps in atopies 
if not in normals, and possibly correlating with eosinophil counts. 
Multiple determinations, however, were performed on a single un¬ 
known sample and counts for an individual determination differed by as 
many as 1200. With this range of values on a single unknown, it seemed 
doubtful that the method would be reproducible enough to detect the 
relatively subtle changes that might occur throughout the course of a 
day. 
Testing the hypothesis of circadian rhythms of IgE must await 
either 1) demonstration of greater reproducibility of values of unknown 
sera or 2) perfection of an alternate method to assay IgE, 
(C) Ontogeny of the IgE Responses; 
The Effect of Ant^-Heavy Chain Antisera 
Investigating the ontogeny of the IgE response in mice was a major 
concern of this thesis project. While the results could not directly re¬ 
solve the relation between IgE and neoplasia, furthering the understand¬ 
ing of IgE production cannot help but bring us closer to elucidating the 
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role of IgE in host reactions to malignancies, 
Kincade and Cooper first described treating chickens with anti¬ 
heavy chain immunoglobulin."^ When given in oyo injections of 
anti-mu, that is antisera directed against the heavy chain of chicken 
IgM, bursectomized chickens not only failed to produce IgM, but also 
could not synthesize IgG, Working with neonatal, germ-free, Balb/C 
mice, treatment with anti-mu chain immunoglobulin also prevented 
production of the immunoglobulin classes, ^-^>-^3 K,G, <& A. Treatment 
with anti-gamma chain prevented IgG and IgA responses, but not the 
response of IgM. Finally, intraperitoneal injections of anti-alpha chain 
precluded the appearance of IgA, but did not affect IgM or IgG. The 
explanation offered by the authors is that ontogenetically the mouse’s 
E-cells progress from a sequence of producing IgM to IgG to IgA. The 
anti-heavy chain antisera interrupts this sequence theoretically either 
by having a lytic effect on the E lymphocytes or by interfering with 
their membrane receptors. 
This work has been repeated by other investigators in mice that were 
not kept in a germ-free environment^-^»and in random bred animals 
The effect of anti-heavy chain has also been studied on lymphocytes grown 
T 7A "I 7Q 
in vitro." * Studies have confirmed the initial reports with the 
modification that IgA producing cells may come directly from IgM precursors. 
144 i o 
* J No reported study has concerned itself with relationships of 
IgE to the sequential development of immunoglobulins M, G A, but the 
question has considerable clinical importance. 
Several investigators have measured IgE concentrations in patients 
with hypogammaglobulinemia, including common variable ’acquired’ and 
Eruton’s sex-linked hypogammaglobulinemia.*232,184,8?,269 Each study 
has shown that greater than ninety percent of hypogammaglobulinemic sub- 
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jects have depressed levels of IgE. However, lot'? levels of IgE, as 
has been mentioned, are difficult to measure. Normal serum levels 
of IgE are less well established and vary more widely than the nor¬ 
mal levels of other immunoglobulins. Subjects who are apparently 
132 184 
completely normal and who have absent IgE have been reported. * 
Possibly some of these depressed levels of IgE in these hypogammaglo¬ 
bulinemia subjects are within normal range. 
Several pieces of evidence suggest that IgE might have an on¬ 
togenetic development independent from the M to G to A progression. 
First, Ishizaka et al. have studied the production of IgE in vitro in 
95 primed lymphocytes treated with anti-mu sera, 'These lymphocytes were 
able to produce IgS despite the presence of anti-heavy chain sera and 
the reduction of other immunoglobulins. However, because this work was 
done with primed lymphocytes, i.e. lymphocytes that had been exposed to 
antigen prior to the treatment with anti-mu and re-exposure to antigen, 
the study merely indicates that the cells producing IgE were unaffected 
by anti-mu but says nothing about the possible ontogenetic precursors of 
these IgE-bearing cells. 
Second, although acquired hypogammaglobulinemia is not a single 
2 69 
entity, but a group of disorders with a variety of causes, ’ 7 some 
hypogammaglobulinemia subjects retain IgE despite loss of other immuno¬ 
globulin classes. In an experimental model in rabbits, it is possible 
to stimulate IgE without detectable antibodies of other classes appearing 
In doing immunofluorescence studies on lymphoid tissue, Tada and Ishizaka 
reported on one hypogammaglobulinemic subject who appeared to retain 
a normal number of IgE-bearing lymphocytes despite markedly depressed 
268 
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221 plasma cells or P-cells of other immunoglobulin classes. Two 
other similar patients were devoid of IgE as well as IgG, K, or A 
bearing cells„ A recent case report describes a hypogammaglobulinemia 
patient x-rho retained normal levels of IgE and suffered from a malab¬ 
sorption syndrome,^"' 
Third, many patients with hypogammaglobulinemia develop anaphylac¬ 
toid symptoms when being treated with passively administered gamma 
globulin.59 Both these observations suggest that the synthesis of IgE 
may be preserved while other immunoglobulins are absent. Schumacher 
and Ellis, however, have studied several hypo gamma globulin emic s and 
demonstrated that their basophils do not release histamine in the 
presence of foreign gamma globulin indicating that the anaphylactoid 
responses may not be due to IgE-mediated reactions, 
67 Fourth, Gajl-Peczalska et al, ' reported a case of Eruton*s sex- 
linked agammaglobulinemia in which the subject had demonstrated allergic 
symptoms and had apparently a normal number of circulating IgE-bearing 
lymphocytes while B-cells of other immunoglobulin classes were virtually 
absent. Because of the possible confusion between basophils and IgE- 
bearing lymphocytes when studied by immunofluorescence, the conclusions 
195 78 
of this study have been questioned. A second case report' describes 
another child with Bruton's hypogammaglobulinemia who had positive 
immediate hypersensitivity skin tests and who reacted with a wheal and 
flare to injections of anti-IgE, thus demonstrating the presence of IgE 
on his mast cells despite absent serum levels of other immunoglobulins. 
Finally, occasionally patients with severe combined immunodeficiency, 
a condition with depressed T-cell as well as B-cell function, will have 
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2o7 
an 'elevated serum IgE," while other immunoglobulin levels are 
typically depressed.^ 
With this conflicting evidence relating to the ontogeny of IgE, 
we studied the production of IgE in mice treated with anti-mu sera 
from birth. 
Methods: 
Antisera- Goat anti-mouse mu sera (lot 4066? and/er lot 40900) was 
purchased, commercially from Meloy laboratories, Springfield, Virginia, 
An absence of anti-light chain activity, kappa or lambda, or anti-heavy 
chain activity other than anti-mu was demonstrated with Ouchterlony gel 
diffusion plates. The purchased antisera was preserved with sodium 
azide and was dialyzed against sterile saline to remove this preservative 
prior to injection into animals. Control animals were injected with bevin© 
gamma globulin (EGG), Cohn Fraction II, Sigma Chemical Co, EGG was dissol¬ 
ved in sterile saline at a concentration of 10 mg/ml, passed through a 
0,20 micron millipore filter, and stored in sterile glass syringes until 
ready for use. 
Animals- Mice were provided from the specific pathogen free colony of 
the Biobehavioral Science Research Center of the University of Connec¬ 
ticut, Storrs, Connecticut, at a nominal cost. In the preliminary work, 
DBA/l mice were selected for treatment with anti-mu as these mice are 
especially reactive to evalbumin (0A), an antigen for which IgE anti¬ 
bodies can be readily demonstrated by passive cutaneous anaphylaxis (PCA) 
(see below), 
A number of difficulties forced us to abandon the use of DBA/l 
mice. First as mothers, these mice are particularly temperamental and 
it was necessary to use surrogate C57B1/10 or C57B1/6 lactating females. 
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Second, the animals produce small litters. Third, the animals are 
relatively small in size. And fourth, these mice were especially 
sysceptible to stress and infection. Although we began with roughly 
forty DBA/1 infants, only seven (four experimentals and three controls) 
were able to survive to the end of the experiment thirty-four days 
after birth. 
Of these experimental animals that did survive, all were runted 
when compared to the controls. The weights of the two groups were 
statistically different by Students' T test, p< 0,0001, Thus, it was 
impossible to tell if the immunoglobulin titers produced by the experi¬ 
mentals reflected the effect of immunosuppression by anti-mu or the effect 
of the runting itself. 
These problems were minimized in subsequent experiments with the 
use of the first generation products of the mating of DBA/l males and 
C57B1/10 females. These animals had a number of advantages. The litter 
size was larger. The animals were healthier. The need for surrogate 
mothers was obviated. And the reactivity of these animals to 0A was 
230 
at least as great as the reactivity of the DFA/ls. " 
Male and female six x%reek old Swiss mice from the Sterling Hall of 
Medicine colony, Yale University Medical School, were used as recipi- 
ents of sera to titer IgGl antibodies by PCA. Preliminary work had 
shown these mice to be comparable to CFW mice (Carworth Farms, Mew City, 
New York). CFW are a standard breed used by other investigators for PCA 
131 
work. Two huridred gram male Sprague-Dawley rats were purchased from 
Charles River Laboratories, and used as recipients for IgS titration by 
PCA as described by Mota and Wong‘S’ and Konig et al.^^ 
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Injection schedule- The schedule for treatment with anti-mu varied 
slightly from litter to litter, but in most cases, neonatal DBA/l 
x C57E1/10 mice received their first injection, either antisera or 
EGG, x-riLthin twenty-four hours of birth. This was considered to be 
day one. Animals x-rere given 0,05 cc on days one through four intra- 
peritoneally (i.p.) and 0.10 cc on days 9* 16, and 26, The total dose 
was therefore 0.50 cc. On day 21 all animals were given an i.p. 
injection of ovalbumin (OA) (twice recrystallized, Worthington Bio¬ 
chemical, Freehold, N.J.) 0.1 ug dissolved in saline plus alum, 1.12mg 
in a total volume of O.lcc, The alum was prepared as described by Levine 
and Vaz^^ and had a dry weight of 28 mg/ml. On day 34, thirteen days 
after exposure to antigen, all animals were placed under light ether 
anesthesia and bled repeatedly througjkthe retro-orbital plexus with 
glass pipettes. Approximately 0,20 cc of serum was obtained per animal. 
Titration of immunoglobulin levels- 
177 44 A) PCA; This technique has been well described by Ovary and others. 
In brief, mouse sera contains two immunoglobulin classes of reaginic 
antibody, IgE and IgGl.^>^^ Reaginic antibodies can be thought of as 
those immunoglobulins that can passively sensitize the surface of mast 
cells or basophils and which cause the release of serotonin, histamine, 
and/or other vasoactive substances from these cells when exposed to 
appropriate antigentic stimulus. Unlike IgGl, IgE activity can be destroyed 
o 34 
by heating at 56 C or by treatment with 2-mercaptoethanol. In mice, 
activity of passively injected IgE will persist after 48 hours by which 
time essentially all IgGl activity has disappeared. 
To titer XgGl, sera was diluted with saline in a two fold manner 
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beginning at a concentration of one to five. The backs of Swiss mice 
were shaved and after light ether anesthesia, 0,03 cc of diluted serum 
was injected intradermally into the shaved surfaces. Up to four injec¬ 
tions of varying dilutions were given per back. After two hours, the 
recipient mouse was again given ether anesthesia and 0.15cc of saline 
with 0.7$ 04 and 0.4$ Evans blue (Matheson, Coleman, and Eell, E. 
Rutherford, N. J.) was injected intravenously via the retro-orbital plexus. 
One half hour after that, the animals were sacrificed and reactions read 
by removing the skin from the back of the animal and observing the blue¬ 
ing at the injection site. Theoretically immunoglobulin from the pass¬ 
ively administered serum will sensitize the mast cells in the recipient 
animal. When appropriate antigen is given, the mast cell will degranu- 
late, releasing histamine and/or serotonin. This alters vascular perme¬ 
ability and allows the extrusion of Evans blue, causing the local blueing 
xdiich could be easily read as a positive reaction. The titer of anti¬ 
bodies was considered to be the highest dilution of serum causing blueing 
of 5 mm or more in diameter in at least two of three mice. If a dilu¬ 
tion of 1:5 failed to produce a reaction in a majority of mice, the 
titer was considered to be zero. 
Titration of IgE antibodies in mouse sera can be done in either of 
two ways by using PCA. Recipient animals can either be mice or rats. 
For the mice, administering antigen i.v. 48 to 72 hours after the skin 
has been sensitized will detect essentially only reagin of the IgE class. 
An alternative method is to use rats, as mouse IgE, but apparently not 
IgGl, will bind readily to rat mast cells, , 

Male Sprague-Dawley rats were anesthetized with sodium pento¬ 
barbital (Diabutal, Diamond Labs, Des Moines, Iowa) approximately 
0.80 cc/kg i.p. The back of the rat was shaved and up to 24 in¬ 
jections of 0.05 cc of varying dilutions of sera were given per 
animal. Two hours later tha animal was anesthetized with ether and 
injected i.v. through the dorsal vein of the penis with 1 cc of saline 
containing 0.4$ Ivans blue and 0,7$ 0A. Half an hour later animals 
were sacrificed under ether and their dorsal skin removed. The titer 
was considered to be the highest dilution causing blueing of at least 
5 mm in two of three animals. 
E) Ouchterlony plates; Presence of IgGl and IgG2 was determined by 
appearance or absence of a precipitation line when serum diluted 1:5 
was allowed to raact on a gel diffusion plate with the appropriate 
class specific antiserum provided by Dr. Philip Askenase. This method 
is described by Arnason.^0 
C) Passive hemagglutination: IgM and IgG antibody levels to 0A were 
measured by their ability to agglutinate sheep red blood Cells (SRBC) 
coated with antigen. Blood was defibrinated and the cells washed. Red 
cells were removed and mixed for four minutes at room temperature with 
3 mg 0.1$ CrCl^^HgO (Malinckrodt Chemical, St, Louis) and 3 ml of 0A at 
a concentration of 10 mg/ml. The treated cells were washed five times 
and resuspended in normal saline at a concentration of 5$® This suspen¬ 
sion was diluted 1:5 in phosphate buffered saline. 
Serum to be evaluated for antibody was tested in serial two fold 
dilutions beginning at a dilution of 1:10. Rabbit hyperimmune antisera 
to 0A was provided by Dr. Philip Askenase and used for control. Untreated 
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serum was considered to reflect both IgM and IgG antibodies. To 
measure just IgG, serum was reacted with mereaptoethanol (Pierce 
Chemical Company, Rockford, Ill,) and tested at dilutions beginning 
with 1:20. To 0.1 ml of serum to be tested, 0.3 ml of 0.133 M 
mercaptoethanol was added and incubation carried out at room temper¬ 
ature for two hours. 
Serial dilutions of serum were added to autotiter hemagglutinat- 
ing plates containing the treated SRECs and the agglutination end 
point read. Antibody titers are expressed as the dilution for which 
agglutination ended. Fifteen dilutions were tested for each sample. 
If no agglutination occurred at the lowest dilution tested, the titer 
was considered to be zero. 
Splenic histology- Spleens were removed immediately after sacrifice 
and frozen in liquid nitrogen. Spleens were stored at -90cCuntil ready 
for sectioning and staining. Microtome sections of four to six microns 
were prepared. Tissue was stained with hematoxylin and eosin and evalu¬ 
ated -with light microscopy. 
Animal survival precautions- Obviously the survival of the animals was 
crucial in the performance of this experiment. Absorption of injections 
without rupture of bowel is a delicate technique in a newborn. These 
injections were skillfully given by Sandra Rosenbaum. To minimize the 
risk of cannabalization, we handled all animals i^ith gloves, and during 
the first few days of life, rubbed the newborns' backs with Vicks Vapo 
Rub (Vicks Chemical Co, Hew York City, NY) immediately after injection 
in an effort to discourage the mother from injuring the litter and to 
minimize odor from handling. 
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Results : 
The results of treating DRA/l X C578B1/10 mice with anti-nra 
antisera and then immunizing with OA are given in Table II. Mean 
values and standard deviations for the EGG treated and the anti-mu 
treated groups are given in Table III. 
Immunosuppression clearly was achieved, Students' T test, 
the difference between the two groups for IgGl values as determined 
by PCA was significant with p<0.025. Similarly, comparing the IgM 
and IgG values as determined by FKA showed p<0.005. P<0.01 for the 
comparison of IgG levels as measured by PHA. In contrast, the IgE 
values did not differ significantly between the two groups (j3>0.3). 
Splenic histology is pending. 

TABLE II. RESULTS OF ANTI-MU TREATMENT ON 
IMMUNOGLOBULIN PRODUCTION 
Litter Animal Treatment Weight Sex 
(gms.) 
IgB 
by 
PCA 
1 A ANTI-MU 5.8 0 
B ANTI-MU 9.3 40 
h CfD* BGG 4.2 
5.2 
20 
E BGG 10.8 12802 
2 A ANTI-MU 15.0 160 
B ANTI-MU 19.0 40 
C BGG 18.2 320 
C BGG 16.9 160 
3 A ANTI-MU 14.9 320 
B BGG 13.6 640 
C ANTI-MU 14.2 12802 
D ANTI-MU 16.3 320 
E BGG 15.7 80 
F BGG 14.9 80 
4 A ANTI-MU 17.0 640 
B BGG 15.8 12802 
C ANTI-MU 15.9 640 
& & 
£ 
>> u 
A © HP CM A IgGflgM IgG IgGl by •p H A 
by. by o o M pJ o o 
FRA PEA PCA M O 
0 0 0 + 0 
0 0 0 + 0 
0 0 0 N.T.5 N.T.5 
50003 640 160 4+ ++ 
80 0 0 + + 
0 0 0 + + 
1280 80 5 + + 
640 40 0 + Hr 
320 80 0 + + 
50003 1280 80 + + 
160 0 10 0 0 
10 0 0 0 0 
S
 
«*
 ©
 
o
 
1280 to + 0 
50003 320 40 + 0 
1280 160 40 + 0 
50005 160 160 + + 
160 0 0 + + 
1 AH sera tested at 1:5 Dilution 
2 Not tested at dilution greater than 1280 
3-Values over 5000 are rounded to the nearest thousand 
4 The small size of these two animals necessitated combining their sera for 
5 NT = Not tested titration 
r 
» 
TABLE III MEAN VALUES AND STANDARD DEVIATIONS FOR 
IMMUNOGLODULIN LEVELS OF ANTI-MU AND BGG TREATED MICE 
Treatment IgE by IgG} by IgG + IgM IgG 
by 
p&di PGA El PHA PHA 
Anti-Mu 382 + 391 5.6 + 12.6 223 + 387 27 + 53 
BGG 482 + 495 60,6 + 62,7 3990 + 3055 475 + 502 
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The data indicate that while treatment with anti-mu produced 
a statistically significant reduction in anti-OA antibodies of the 
IgM and IgG class, anti-OA of the XgE class was not similarly 
affected. The lack of dramatic differences between the two groups 
in total serum IgGl and IgG2 as measured by Ouchterlony technique 
can be explained by maternal antibodies, especially as animals were 
either not weaned or weaned just prior to the termination of the 
. 145 
experiment. 
While a number of clinical and experimental observations on 
individuals with hypogammaglobulinemia as <■. > referred to earlier might 
have suggested this result, the outcome nonetheless seems counter to 
the fact that most hypogammaglobulinemic persons have a significant 
reduction in IgE. 
Another piece of experimental evidence would certainly seem to 
suggest that anti-mu treatment would decrease serum IgE. Taniguchi 
and Tada have recently shown that a solubilized fraction of T-cells 
can serve a helper function in immunoglobulin production.This 
helper molecule can be absorbed by anti-mu. They believe that the 
helper activity may be an IgT, an immunoglobulin on the surface of 
the T-cell. Unlike IgG, passively administered IgK in small amounts 
go 23_S 
acts to enhance the production of immunoglobulin including IgE. 
One speculation would be that this effect is mediated by priming 
helper T-cells. 
One would expect then that treatment with anti-mu would exert a 
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significant effect on IgE production if only by virtue of its po¬ 
tential action on T-cells. 
Abundant evidence, however, indicates that the effect of anti-mu 
is independent of T-cells. In in vitro spleen cell cultures, T- 
cells can be removed, but the effect of anti-mu will not be dimin¬ 
ished,^^ Anti-mu antibodies have a suppressive effect even if the 
123 
antigen is thymus-independent such as ferritin. Anti-mu antibodies 
can prevent the transplantation of such B-cell tumors as Friend leu- 
149 146 
kemia virus leukemia ' or myelomas. ' And anti-mu does not effect 
such T-cell functions as skin graft rejection.and possibly helper 
function itself. 
Still specific T cell functions may be attributable to sub- 
203 2 37 populations of T-cells and a subset responsible for assisting 
or suppressing the ontogenetic development of the B-cell line might 
be affected by anti-mu while other T-cell functions are undisturbed. 
If work substantiates that some T-cells bear an IgT with mu chain 
223.261 
determinants, one would predict that anti-mu treatment should 
affect T-cell function, including helper function in the production 
of IgE. In our work, either helper function was unaltered or a second 
effect of anti-mu compensated for diminution in helper function and 
permitted normal serum IgE levels. 
While treatment with anti-mu suppresses IgK, IgG, and IgA, a re¬ 
turn to normal levels of IgA despite prolonged treatment with antisera 
has been reported.l^sl^ j_s unij^ely that such a rebound is also 
occuring with IgE because the return of IgA values was observed only 
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after six weeks of treatment whereas at three weeks, the crucial 
time in this experiment when animals were exposed to antigen, IgA levels 
were always still markedly depressed. Since, however, the timing and 
extent of the reappearance of IgA is dependent on the dose of anti- 
mu,l46 we are conducting studies to determine if increasing the 
dosage of antiserum might result in a significant depression of IgE. 
This experimental model utilizing anti-heavy chain immunoglobulin 
has potential for elucidating other aspects about the physiology of 
IgE. For example, the question of affecting IgE levels by selectively 
suppressing IgA is especially relevant as some have suggested that the 
true immunological defect in atopy is not an excess of IgE but a 
transient deficiency of IgA, which may be the only truly significant 
blocking antibody,^ As IgE and IgA may both be important fac¬ 
tors in the immune response in breast carcinoma (see p. 19), this work 
could help elucidate the relationship of these two immunoglobulins 
in response to malignancy. 
Treating mice with anti-gamma 1 and/or anti-gamma 2 may help 
clarify the relation between IgG and IgE. A tradiational view holds that 
IgG is the principle blocking antibody and that IgG levels may be 
inversely related to IgE. Support for this hypothesis came when Tada 
and Okumura showed that rats given IgG passively produced markedly 
222 
depressed IgE titers. However, this report could not be reproduced 
by tie Ishizaka and Okudaira'^ in mice, nor could the Ishizakas show 
an inverse relationship between IgG and IgE levels during the course of 
long tem hyposensitization immunotherapy.91 ^ treating slightly older 
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mice with anti-gamma we might be able to inhibit IgG selectively 
and analyze the relationship between ’blocking* IgG and IgE. 
Thus, results so far indicate that synthesis of IgE is either 
independent of the ontogenetic progression of other B lymphocytes 
from IgM to IgG to IgA or IgE may actually precede IgM in ontogeny. 
Current work is in progress to verify these results, especially with 
higher doses of immunosuppression, and to elucidate the effect of 
anti-alpha antiserum on IgE production. 
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PART III; Tumor-Related Studies 
(A) IgE Responses to Tumor in Animals 
As discussed in the literature review, Bartholomaeus and 
Yeast in 1972 reported that mice could make IgS responses to 
tumors. We attempted to repeat their work as a preliminary 
to answering some of the following questions: Does an IgS res¬ 
ponse alter the course of the malignancy? Could passive transfer 
of IgE affect tumor challenge or the course of an already trans¬ 
planted tumor? Is the immunotherapeutic effect of certain adju¬ 
vants like B, pertussis related to is effect on IgE response? 
While Bartholomaeus and Keast had shown that IgS could be pro¬ 
duced, they had not addressed themselves to any of the above ques¬ 
tions , 
To assess the role of IgS we attempted to produce a variable 
antibody response by using a range of immunizing doses of tumor 
and two different adjuvants, 
Methods; 
Animals- Male and female AKD2F1/J, DBA/2J, and C5?8l/6j mice were 
purchased from Jackson laboratories, Bar Harbor, Maine, Swiss mice 
were obtained from the Sterling Hall of Medicine colony, Tale Medical 
School, CFW mice were purchased from Carworth Farms, Hew 1'■: ’ City, 
New York, Lems rats were purchased from Microbiological Associates, 
Recipient animals for PCA titrations were either Swiss or CFW mice 
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or the rats. The Lewis rats had been shown to be comparable to 
iprague-Dawley rats in PCA reactions to OA as described in the 
previous section. 
Tumors- A murine lymphoma, L5178Y, maintained in vivo was pro¬ 
vided for us by Dr, Robert Capizzi. Ms tumor was initially re¬ 
ported in DEA/2 mice and in our hands took readily in AKD2F1/J mice 
at i.p. doses of 1<P to 10^ cells. Death preceded by ascites 
occurred regularly in 10 to 18 days depending upon the number of 
malignant cells initially injected. This tumor was selected be¬ 
cause some immunological aspects of its growth had previously been 
studied^»^anc^ ^t was ciear that injecting animals with 
irradiated cells could produce immunity,^ 
The murine melanoma, B16, was given to us by Dr. Ted Reid, who 
maintained an in vitro cell line. This tumor took readily in C57EL/6 
mice and caused death in 1? to 35 days. It is the same tumor as initi¬ 
ally reported upon by Bartholomaeus and Feast. 
Immunization of animals and serum collection- For the work with L5178Y, 
a variety of mice strains including AKD2F1/J, DBA.2J, CFW, Swiss, and 
C57HL/6J were given injections of tumor in doses ranging from 1.4 x 10^ 
to 2.8 x 10^ cells. The cells were usually viable, but in some instances 
they were Irradiated prior to injection. Either an i.p. or a subcutaneous 
(s.c.) route of injection was used. Cells were either given without 
adjuvant, with 1 mg of alum, or with killed B. pettussis organisms (Eli 
Lilly and Co., Indianapolis, Ind.) with the number of bacteria varying 
from 9.6 x 10^ to 4,4 x 10^ depending on the trial. Alum was prepared as 
181 previously described. Mice were bled from seven to nineteen days after an 
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an initial injection of cells or following a booster injection of 
tumor. 
For work x$ith the Bl6 melanoma, 6 C57E1/6J mice given a s,c. in¬ 
jection of 3 x 105 cells plus 1 mg, of alum. Serum was obtained from 
these mice one and two weeks after immunization. 
For all animals, bleedings and i.v. injections were usually 
performed with the animal under light ether anesthesia. 
Irradiation- "When cells were irradiated, a Semens x-ray machine was 
used with a 2 A1 filter, When set at 250 KV and 15 ml, this machine 
delivers 500 rads/min. Three to five thousand rads were given cells 
depending on the trial. 
Passive Cutaneous Anaphylaxis (PCA)- PCA reactions were performed 
as previously described with recipient animals including Swiss and 
CFW mice and Lewis rats. Antigen prepared from tumor cells was given 
in the solubilized forms as described below. Antigen was usually 
given i.v,, but in some trials the antigen was given intradermally (i,d.) 
directly into the site that had previously received serum passively. 
"When antigen was given in this manner, a control injection of antigen 
into unsensitized skin was also tested. 
Active Cutaneous .Anaphylaxis (ACA)~ In a few instances, antibody res¬ 
ponse was assayed by injecting an animal with antigen i.d. some time 
after that animal had been actively immunized with tumor cells. The 
animal receiving the i.d. injection would first be shaved, receive the 
injection of intradermal antigen, then immediately receive an injection 
of Evans blue x^ith saline i.v. Thirty minutes later tha animal would 
be sacrificed and reactions judged from the underside of the skin. 
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Control reactions included injection of saline instead of tumor 
antigen and injection of tumor antigen into non-immunized animals. 
Positive reactions may be attributable to either IgS or IgGl, 
Solubilization of tumor antigen- A positive reaction in PCA requires 
that antigen react:on with IgS on the surface of a basophil or mast 
cell. For steric reasons, we believed that this reaction would be 
difficult to elicit without first solubilizing the tumor antigen. Al¬ 
though in a few instances whole tumor cells -were used to attempt to 
elicit the PCA reaction, we generally solubilized the antigen by one 
or more of the following procedures: rapid freezing and thawing in a 
dry ice-acetone bath; ultrasonication with a sonifier call disruptor, 
Model W185D, Heat systems-ultrasonics, Inc,; ultracentrifugation at 
30,000 RrM or at 30,000 g for one hour; irradiation with three to five 
thousand rads; and extraction with 3 M PCI as described by Meltzer et 
162 
al. In order to elicit PCA reactions, antigen was administered i.v. via 
the retro-orbital plexus in the mouse or via the dorsal vein of the 
penis in the rat. Either Evans blue was added directly to the tumor 
antigen or a second injection of saline plus Evans blue was given imme¬ 
diately before or after the injection of tumor antigen. An initial con¬ 
centration of greater than 10^ cells/ml. and usually greater than 10 ^ 
cells/ml was always used to begin the solubilization process. 
Foot pad testing- An index of delayed hypersensitivity response to 
jLi'jySY was assessed by injecting appropriate antigen into the foot pad of 
immunized mice. Antigen injected into one foot was 0.04 ml of irradiated 
cells at a concentration of 1.25 x 10 cells/ml. The other foot pad re¬ 
ceived 0,03 ml of tumor antigen extracted with 3 M KC1, Foot pad thick- 
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ness was measured prior to injection and twenty-four hours after 
antigen. Mice tested included 3 AKD that had received leP L5178Y 
8 ^ 
plus 10 B. pertussis, 3 Swiss that had received ICr L5178Y twice 
with two weeks separating the immunizations, and 3 Swiss mice that 
had received no exposure to tumor. Mice that had been immunized were 
tested twenty days after the initial injection of tumor. 
Results; 
Using the tumor, L5178Y, despite the variety of animals immunized, 
the range of bleeding times, the types of adjuvants, the varied routes 
and doses of immunogen, and the alternative methods for solubilizing the 
antigen, we were unable to produce consistent PCA reactions for either 
IgS or IgGl. 
Results are summarized in Tables IV and V, 
A description of a typical experiment should clarify the procedure 
followed. 
Five groups of four AKD2F1/J mice were given i.p. injections of 
■) 
irradiated (3000 rads) L517&Y cells in doses ranging from 3 x 10 to 
3 x 10^ cells. Cells were given with 1 mg of alum in an i.p. injection 
of 0.2 cc. Although 3»000 rads has been reported to destroy the activity 
of L5178Y, by day 18, the majority of animals having received the 
maximum tumor dose were dead. The survivors of this group were bled on 
this day and all other groups were bled the next day. Mice in all other 
groups shox-xed no signs of illness and were disease free for at least an 
additional six weeks. Serum was pooled and frozen at -20°C until ready 
for use, L5178Y cells in a concentration of 9.6 x 10^ cells/ml. were 

TABLE IV PCA REACTIONS TO L5178Y FOLLOWING 
PRIMARY EXPOSURE TO TUMOR ANTIGEN 
Mouse Tumor immunizing § g ^ PCA 
Strain Dose (cell#) test Comments 
and Tadjuvant ® g 8 antigen(s) 
Number 
of 
Animals 
Tirradiation 
:ge rt 1 ® Q *H m 
19 1 Freeze/thaw x 3; 4AKD 3 x 101 l.p. +alum No morbidity from tumor 
irradiated Ultrasonicate; 
Utracentrifuge 
4AKD 3 x 10 l.p, +alum 19 30,000 RFM No morbidity from tumor 
4AKD 3 x 103 l.p, +alum 19 No morbidity from tumor 
4AKD 3 x 10** l.p. +alum 19 One of three animals 0 
for IgE at 1:3 Dilution 
3 x 10^ l.p. +alum 
No morbidity 
4AKD 19 No morbidity from tumor 
5AKD 2,5 x 10^ l.p. + Per¬ 18 Animals dead or moribund 
tussis irradiated by Day 18 
3AKD 103 l.p. 7 1 Whole cells, Animals dead Day 15 
3AKD 
8 ie8/ml 
1(P l.p. + 10 pertu- 7 2 Irradiated cells No morbidity from tumor 
ssis 3 Sonicated cells 
3 SWISS 103 l.p. 7 No morbidity from tumor 
3 SWISS 103 l.p, + 10® pertu- 7 No morbidity from tumor 
ssis 
3AKD 2.8 x 106 l.p. 9 1 Freeze/thaw x 3t 
o Ultrasonicate; Also negative at 14 days 
4AFW 1.4 x 10*7 l.p. 9 Ultracentrifuge by ACA 
30,000 g Also negative at 14 days 
4CFW 1.4 x 10 l.p. 9 2 Whole cells by ACA 
4CFW 1.4 x 10l l.p. 9 Also negative at 14 days 
10 1 Freeze/thaw x 5 
by ACA 
5C57B16 10° + alum S.C. Minimum dilution tested 
1:2; No morbidity from 
4DBA/2 
tumor 
10 + alum S.C. 8t©10 Minimum dilution tested 
c 1:2; Death 12 days 
6CFW 10° + alum l.p, 
103 + 10® pertussis 
10 Minimum dilu. tested 1:2 
No morbidity from tumor 
3AKD 14 1 Irradiated cells No morbidity from tumor 
l.p. 2 KC1 extract 
3AKD 103 l.p 3 Intrademal KC1 
Extract 
Animals dead Day 15 
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solubilized by freezing and thawing three times, ultrasonicating 
with the sonifier intensity set at 4,5 and 7 bursts of 3 to 5 seconds 
given to the suspension of cells surrounded by an ice water bath, and 
ultracentrifuging at 30,000 RPM for one hour. The supernatant was 
used as the antigen to elicit PCA reactions. 
Each of the Swiss and CFW mice recipients for PCA titration re¬ 
ceived 0,1 ml. of antigen i.v. This administration -was given either 
two or 48 hours after the animal had been passively skin sensitized 
with a dilution of serum of at least 1:5 from the actively immunized ani¬ 
mals. With one exception no positive reactions were elicited. The 
one exception occurred after a 48 hour sensitization period at a 
dilution of 1:5 with serum from the group that had received 3 x 10^ 
cells, but as this reaction occurred in only one of three animals, it 
was not scored as positive when (judged by criteria generally used for 
scoring PCA reactions, namely a positive response in the majority of 
animals tested. 
ACA responses in Swiss mice that had received ICp leukemic cells 
26 and again 12 days previously were tried with irradiated cells and 
with the hypertonic KC1 extract. Reactions in the immunized mice did 
not differ from controls. 
Experimentation with the Bl6 melanoma also did not produce consis¬ 
tently psoitive results. As described in the methods section, 6 C57 
mice were immunized with a s.c, dose of melanoma and alum and then bled 
7 and 14 days after immunization. The sera was pooled from each bleeding 
and diluted 1:5 with saline. Tumor antigen was solubilized by harvesting 
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5 x 10 ^ cells growing in vitro and “freezing and thawing them 
rapidly five times in a dry ice-acetone bath. Four Swiss mice 
were skin sensitized and two hours later each received an injection 
of Pvans blue i.v, followed by 0,15 ec of the solubilized antigen. 
In each case the mouse receiving antigen died within ten minutes of 
the intravenous injection of an apparent cardiorespiratory arrest. 
Death was clearly not due to the ether anesthesia that had been used 
to facilitate the giving of i.v, injections as usually the animal was 
visibly recovering from the ether before respiratory difficulties 
developed. Death was also not due to the volume of fluid adminis¬ 
tered as mice in our hands had been shown to tolerate far greater fluid 
loads quite well. Pulmonary emboli from particles in the antigenic 
suspension was considered a possibility, but centrifuging the antigenic 
fluid to remove possible particles did not seem to affect the toxicity 
of the challenge antigen. This antigenic suspension was also lethal to 
animals that had received no passive serum. 
Thirty-four days after receiving the s.c. melanoma injection, three 
of the survivors received an i.d, injection of tumor cells that had been 
ultrasonicated. One of the three animals produced a reaction markedly 
larger than the response produced by a similar injection into unimmunized 
controls. 
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Discussion: 
While the lack of consistent positive results prevented us from ass¬ 
essing the effect of an IgE response on tumor growth in an animal sys¬ 
tem, useful information did emerge from this work. 
In their report on mice producing an IgE response to the Bl6 
melanoma, Bartholomaeus and Keast solubilized the tumor antigen by a 
process of freezing and thawing, ultrasonication, and ultracentrifugation 
While we wished to duplicate their work as closely as possible, we were 
loathe to ultrasonicate and ultracentrifuge the tumor cells, Ultra¬ 
soni cation, if done at too high a frequency, can serve to destroy anti- 
10 ft 
genicity rather than solubilize it. Unfortunately, in their report 
Batholomaeus and Keast did not specify the frequency with which they 
sonicated. We also reasoned that ultracentrifugation would only cause 
the loss of some antigen. For these reasons, in most of our work we 
solubilized the El6 cells only by rapid freezing and thawing, and the 
intravenous administration of this suspension proved lethal to passively 
sensitized animals, 
A personal communication from Bartholomaeus clarified some of our 
difficulties,^ First, the frequency of their ultrasonication was re¬ 
ported as ranging from 16 to 24 KGS, As the ultrasonifier that we 
employed performed at 20 KCS^ ultrasonication would probably not have 
destroyed antigenicity. The positive active cutaneous anaphylaxis res¬ 
ponse obtained in one of three animals using ultrasonicated antigen is 
encouraging and Confirms the idea that sonication would not destroy all 
antigenicity. 
16 
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Second, the author reported that while they had been success¬ 
ful in demonstrating IgE responses with a variety of tumor systems, 
they had been unsuccessful with all leukemias and lymphomas. Hence, 
our failure with L5178Y despite careful adherence to the methods of 
Bartholomaeus and Feast in some of the trials with this tumor be¬ 
comes understandable. 
In trying to interpret our negative results, we could not be 
sure if they arose from a failure of the immunized mice to produce an 
antibody response or from a failure of our antigen to be solubilized. 
The communication from Bartholomaeus re-emphasized the necessity of 
using some solubilization procedure to elicit the PCA. We had some 
evidence that mice were making an immune response to the tumor, namely 
the mouse's ability to survive tumor challenge. For example, 3 AKD2F1/J 
mice were given lCr L5178Y i.p. and three were given an equal number 
Q 
of tumor cells plus 10° heat killed Bordetella pertussis, 16 to 18 days 
after this injection, the animals from the first group were dead. Eight 
weeks after the injection the animals that had received tumor plus B. 
pertussis showed no evidence of disease. As shown in Table IV, despite 
the acquired immunity, we were unable to demonstrate the presence of 
either IgGl or IgE antibodies directed against the tumor in these mice. 
Foot pad testing like^wise failed to demonstrate the acquired immunity. 
While B pertussis has a variety of effects on the immune system, 
many investigators have utilized its potent adjuvant effect on IgE 
responses. Furthermore, several authors have noted that like baeille 
. 
’ 
■ 
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19 76 127 48 
calmette guerin ’ ’ and corynebacterium parvum, B. per- 
13 
tussis may be used to prolong survival in animals bearing tumors. 
14,137,247 It has also been tried in immunotherapy of human neo- 
plasia.° Like other immunotherapeutic agents, timing of its 
administration in certain ways may also enhance tumor growth. 
Some authors have speculated that the effect of pertussis on XgE and 
the effect on survival after tumor challenge might be related. With 
this in mind, to attempt to demonstrate IgE in pertussis immunized 
animals seemed logical. Negative results, especially as all the work 
with pertussis was done only in the lymphoma system, do not rule out 
the possibility that IgE might be an important factor in immunotherapy 
with B. pertussis. 
An outgrowth of these experiments was the observation that when the 
B16 melanoma was admixed with alum prior to its inoculation, the sur¬ 
vival time of the mice seemed to be prolonged 50$. The alum was pro¬ 
bably not toxic to the tumor cells prior to the injection, as the alum 
was buffered and in an isosmotie medium, although this possibility was 
not ruled out by examining the viability of tumor cells combined with alum 
in vitro. Alum itself might prove to have some use in tumor immunotherapy. 
We are unaware of other reports suggesting prolonged survival using 
alum as an adjuvant. 
In summary, in an effort to investigate how an IgE response against 
a tumor alters the course of the malignancy, an attempt to show that 
mice could make an IgE response against a tumor was undertaken. Exten¬ 
sive work concerned the lymphoma, L5178T, and a lesser portion of study 
. 
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was devoted to the melanoma, £16„ IgS responses were not consis¬ 
tently demonstrated despite the prolonged survivals, indicating an 
apparent immune response, and the use of adjuvants, B. pertussis and alum, 
which are known to enhance IgS production, Clarification of methods 
in a report describing an IgE response to a tumor was obtained. This 
information along with the knowledge gained in the unsuccessful trials 
should enable this work to be successfully completed in the future. 
(B) IgE Responses to Ovalbumin 
in Tumor-Eearing Animals 
Several reports have stated that individuals with neoplastic 
q *jo ino 
disease have depressed circulating levels of serum IgE, If 
correct, these reports leave unanaswered the question of cause ct ef¬ 
fect. Has a low level of IgE predisposed to the malignancy or did the 
tumor result in depressed IgS? Only a very large prespective study 
would really answer these questions, but xre attempted to gain some 
clues by studying IgS responses in mice bearing tumors and examining 
the effect of tumor inoculation on pre-existing IgE levels in mice. We 
are especially interested in reports of increased IgE in patients with 
Hodgkin’s Disease.9*198,231 -^is is usually attributed to decreased 
3 
T-cell function in what is thought by many to be a T-cell malignancy," 
we studied IgE responses in mice bearing a theta positive lymphoma, 
L5178Y. The theta antigen is found on cells of thymic origin. We also 
assessed the effect of a melanoma on IgS responsiveness. 
Methods: 
Animals- Mice given living tumor cells were C5?®l/6j mice for 
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the melanoma studies or AKD2F1/J mice for the lymphoma studies. 
Both were purchased from Jackson laboratories, Bar Harbor, Maine, 
PCA reactions were titered in Swiss mice from the Sterling Hall of 
Medicine colony (2 hour IgGl reactions) or in Sprague-Dawley rats 
(IgS reactions) from either Camm Research (Wayne, N.J.) or Charles 
River Labs (Wilmington, Mass,), 
Tumors- Either the L51?8Y lymphoma or the Bl6 melanoma were used as 
previously described. While the lymphoma was usually transferred from 
an in vivo cell line, one group of experiments made use of a transfer 
from an in vitro line also maintained by Dr. Robert Ca^pizzi. 
Irradiation- Cells were irradiated with 3000 rads as previously des¬ 
cribed. Irradiated cells were used only in Experiment I. 
Antigen- Ovalbumin (2X recrystallized, Worthington Biochemical, Free¬ 
hold, N.J.) was given i.p. in saline at a dose of 1 ug with approxi¬ 
mately 1 mg of alum, synthesized as previously described. Total injec¬ 
ted volume was 0,1 ml, 
PCA Reactions- These were run as previously described with passively 
sensitized mice or rats given i,v. injections of saline plus 0,7 $ 0A and 
0.4$ Evans blue two hours after skin sensitization. Mice were skin sen¬ 
sitized with 0,03 wl of diluted serum while 0.10 ml was used in the rats- 
Results: 
Experiments were designed to test if the transplanatation of tumor 
would affect the IgE response to ovalbumin. Experiments I through III 
involve the lymphoma L5178Y. In experiment I, tumor was given to mice 
that had a pre-existing, high titer of anti-OA antibodies. In experiment 
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II, the tumor was given just prior to the booster antigen. And in 
experiment III, tumor was transplanted just before or after the initial 
exposure to antigen. Experiments IV and V are similar except that 
they involve the melanoma Bl6. In the fourth, animals with a well 
established tumor were exposed to OA for the first time in the fifth, 
animals were given the tumor after a high, boosted antibody titer had 
been established. The data are summarized in the five accompanying 
tables (VI through X), with the data from Table VI also represented 
graphically in Figures II and III. Essentially animals bearing tumors 
were able to make IgE and IgGl responses comparable to controls and once 
an animal had been immunized, transplantation of a tumor did not 
greatly reduce the antibody response, although a tendency toward de¬ 
pression of the antibody response was seen in some instances. 
A few specific comments about each of the experiments are in order. 
In the first, (Table VI), high PCA titers were established by immunizing 
mice with OA and boosting them 28 days later. Several days after the 
c 2 
booster dose, tumor was transferred either in a dose of KK or 10 cells 
with one group receiving 10-^ cells that had been irradiated and one group 
receiving only saline. The graphs (Figures II and III) pictorialize 
that all four groups were within a two fold range of IgE and IgGl 
concentrations at the time of tumor transplantation. The mice that 
received 10^ cells had all died within 10 days. Irradiation only slightly 
delayed the death so that no animals in this group were living at da3/" 15 
after tumor transfer. All mice that received NaCl or 10^ cells survived. 

Effect of L5178Y on ongoing, boosted Antibody Response 
Table VI Experiment I 
# of Tumor Day IgE Titer-Day* IgG-^ Titer-Day* 
Strain Dose Antigen 
Animals Cell # Given 7 12 17 22 27 7 12 17 22 27 
6 AKD .lcc 
-35,-7 640 320 160 160 160 1280 1280 1280 2560 1280 
NaCl 
6 AKD 10^1. p. 
-35,-7 640 160 80 640 1280 320 
6 AKD 102l,p. 
-35,-7 $40 320 160 80 80 640 1280 640 1280 1280 
6 AKD 105l.p. 
-35,-7 320 80 40 43* 1280 1280 640 640 
irradiated 
♦Number of day is relative to last exposure to antigen 
Serum from Day ?was collected prior to transfer of tumor 
♦♦Serum was collected on Day 21 as animals were moribund at 
the time and all dead by Day 22 
Blank spaces in table indicate all animals were dead by 
that bleeding date 
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As can be seen, the IgS levels did tend to drop faster and to lower 
levels in those mice dying from tenor, but as two fold differences 
were obtained in identically treated groups prior to tumor trans¬ 
plantation, the four fold differences seen after tumor implantation 
are suggestive but may not be significant, IgGl levels tended 'to 
decline even less as compared to controls. 
In experiment II (Table VII), antigen was given and then tumor 
was transferred just prior to the booster dose of antigen. The mice 
receiving tumor were dead or grossly ascitic fourteen days after tumor 
transfer. While the IgS levels do not differ significantly between the 
two groups, a marked decline in IgGl levels is noted in the tumor- 
bearing mice just prior to death. 
In experiment III (Table VIII), responses to the primary exposure 
to antigen were assessed, that is, not booster doses of OA were given. 
Tumor that had been maintained in vitro was injected either two days 
after antigen, the same day, or three days before. One group received 
the tumor s.c., a route of injection that permits slightly longer survi¬ 
val, and then was not given antigen until 12 days later when the tumor had 
been well established. One group was given tumor cells that had been 
frozen several months. As can be seen from the chart, all groups except 
the one receiving frozen cells produced IgS and IgGl responses varying 
at most by a factor of two when compared with the controls that had re- 
ceived no tumor. The large majority of these animals died within 18 days 
of exposure to tumor with one animal surviving completely and one 
surviving to 22 days. If an animal did not appear ascitic when others in 
r, • * • •• 
Transfer of L5178Y Prior to Secondary Exposure to Antigen 
Table VII Experiment II 
# of 
Animals 
Strain 
Tumor 
Dose 
# of cells 
Day Antigen 
Given Relative 
to tumor 
transfer 
IgE titer 
♦Day 5 *Day 11 
IgG-^ titer 
♦Day 5 *Day 11 
3 AKD 1.2 x 105 
l.p. 
-24, + 3 320 160 160 160 
3 AKD None -24, + 3 320 160 320 1280 
♦Number of day is relative to last exposure to antigen 
* 
Effect of L51?8Y on primary exposure to Antigen 
Table VIII Experiment III 
Day Ag IgE titer IgG^ titer 
# of e+ . Tumor Dos© Given 
strain ^ cf cens Relative to 
Animals Tumor transfer *Day 12 ♦Day 17 ♦Day 12 *Day 17 
5 AKD 2 x 104 l.p. 0 20 5** 
4 AKD 2 x 104 
Frozen 
l.P. 0 5 0 
5 AKD 2 x 104 l.P. -2 80 10 10 0 
5 AKD 2 x 104 1. p« +3 80 10 
5 AKD 2 x 104 1. p. +12 40 10 
4 AKD None 0 40 10 5 
♦Number of clay is relative to last exposure to antigen 
♦♦Only two animals tested? dilution positive in 1 of 2 
/ 
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th© group were clearly moribund, it was not bled. This was true 
of the one animal that survived the course of the experiment. Animals 
that received s.c, tumor died at about thirty days after inoculation 
and animals that had received frozen tumor cells also tended to die 
by this date. The death of those animals receiving frozen cells and 
their apparent lack of an IgE response will be commented upon in the 
discussion. 
Experiments IV and V involved the melanoma EL6. In the fourth 
(Table IX), we were attempting to confirm some preliminary data that 
suggested that mice bearing this tumor might be able to make a greater 
IgE response than controls. In this preliminary trial, a group of 
three mice had been given KL6 plus a alum and three weeks later were 
immunized with 0A plus alum. When they were bled one week later, 
their serum had an IgE titer of 1:20 while controls that had just re¬ 
ceived a comparable OA injection had no detectable titer. Neither group 
had detectable IgGl. Experiment IV could not confirm this finding as 
all groups had no measurable titers seven days after exposure to anti¬ 
gen. Thirteen days after antigen the groups still remained comparable, 
except that animals that had received s.c. saline did make a signifi¬ 
cantly higher IgGl titer. No effort was made to repeat this and no 
explanation for it other than individual variation is readily apparent. 
While IgE concentrations for Day 13 were not tested at dilutions greater 
than l:l60, the qualitative response at high dilutions can give an 
approximation of the antibody titer and it was evident that these groups 
would have at most a two fold difference in IgE concentrations. 

Effect of KL6 on primary response to Antigen 
Table IX Experiment IV 
# of 
Animals Strain 
Tumor Dose 
# of Cells 
Day Antigen 
Given Relative 
to tumor 
transfer 
IgE titer 
♦Day 7 *Day 13 
IgG^ titer 
♦Day 7 *Day 13 
Jg 
4 C57 9 x 104 S.C. +20 0 
All 
animals 
dead 
0 
All 
animals 
dead 
4 C57 9 x 104 S.C. 
+ 
Alum S.C. 
+20 0 >160 0 10 
4 C57 AltJns S * C # +20 0 Zl60 0 10 
4 C57 Saline S.C. +20 0 2160 0 80 
♦Number of day is relative to last exposure to antigen 
• w, 
-51- 
In the final experiment (Table X)» mice that had been immun¬ 
ized with OA were given a booster dose 28 days later and a s.c. dose 
of tumor six days after that. On the day that the tumor was given, the 
controls had a two fold lower concentration of IgE and a four fold 
higher concentration of IgGl. These differences tended to disappear 
after one group was exposed to tumor, It should be noted that some of 
the titrations in this trial did not always establish the precise IgGl 
concentration. The qualitative response at high dilutions suggested 
that IgGl concentrations did not differ widely. As the primary purpose 
of the series of experiments was to examine IgE responses with IgGl res¬ 
ponses used as control data, precise titration of the IgGl response 
was unnecessary if the IgE concentrations were within a two fold range. 
Discussions: 
The data lend little support to the idea that low levels of IgE 
arise from depressed IgE responsiveness during malignancy, but pre¬ 
existing antigen-specific IgE titers do tend to fall after a tumor is 
transplanted. However, In interpreting the data one should consider 
that: first, the method, may not be sensitive enough to detect decreased 
IgE responsiveness. For example, in experiment I four fold differences 
were noted between the IgE levels of tumor-bearing mice and the controls. 
These are suggestive differences, but as two fold differences occurred 
among groups of animals treated identically just prior to the tumor 
transfer, this four fold difference might be within experimental limits. 
230 
IgGl levels supposedly reflect levels of total antibody response. 
Our data also suggest that tumor-bearing mice made a decreased IgGl 
response, but again the limited sensitivity of the method makes such a 

Effect of B16 on secondary response to antigen 
Table X Experiment V 
Tumor Day Antigen 
# of Strain Dose Given Relative Animals # of to tumor 
cells transfer 
4 C57 10?S.C. -34,-6 
4 C57 None -34,-6 
IgE titer IgGj titer 
6 ♦Day 
13 
20 6 ♦Day 
13 
20 
160 40 10 40 > 320 < 160 
80 40 20 160 > 320 160 
♦Number of day is relative to last exposure to antigen 
Titers from Day 6 were obtained from serum just prior 
to tumor transplant 
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conclusion difficult. Evidence in man supports the idea of a de¬ 
creased antibody response in individuals with malignancybut 
209 
reports of normal antibody responses have also been published, 7 
Second, with PCA, iCA, one measures IgE titers for a specific antigen 
while reports in the literature have been concerned with total serum 
IgE, Several studies have shown generally normal or elevated levels 
of other immunoglobulins in most paitients with cancer,25/»2o0 
this may not be indicative of responsiveness to a specific antigen. 
Finally, to draw conclusions about human responses on the basis of 
animal work can be difficult. The most recently published study sug- 
231 
gests that IgE levels are normal in patients with cancer. Our data 
are not inconsistent with this concept. 
The kinetics of the normal IgE response should be compared to 
the IgGl response. IgE levels declined steadily after the booster dose 
of antigen, while the level of IgGl tended to maintain itself or even 
rise slightly. The data suggest a more marked decline in IgE than IgGl, 
This might be explained in part by the muck shorter half life of IgE,^"^ 
at least in human studies, so that decreased immunoglobulin production 
following antigen exposure would become evident sooner for IgE than IgGl. 
As mentioned in the literature review, Hodgkin's disease is unique 
among malignancies in that IgE levels are clearly elevated. Debate 
exists as to whether Hodgkin's disease is a T-cell or B-cell malignancy. 
The traditional view was that Hodgkin's disease must be a T-cell malig- 
39 
nancy because T-cell function both as judged in vivo77 and in vitro is 
3 6> 8 depressed. ' Recent evidence, however, suggests that T-cells in 
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Hodgkin's disease may be quite normal, only depleted in peripheral 
152 
blood. Some claim that the relative number of E-cells is also 
68 
often diminished and others suggest that the characteristic Reed- 
Sternberg cell has Surface immunoglobulin and thus is of B-cell 
12 h, 
origin. Perhaps the concept of T or E-cell malignancy is simply 
not relevant to this disease. 
Regardless of which cell is primarily involved, unquestionably 
a depressed level of T-cell response often characterizes the disease. 
A wealth of excellent experimental data is now accumulating to eluc¬ 
idate the role of T-cells in controlling IgE responses*^*224,225 anj 
the depressed T-cell function is one explanation of the elevated IgE.^° 
?31 
Unfortunately, as alluded to previously, studying IgS responses 
in the mouse model of Hodgkin's disease, the SJL, is most difficult 
because at present they are thought to make poor IgE responses. The 
use of the lymphoma, L51?8Y, seemed to offer a possible i^ay to abrogate 
tile T-cell control of IgE responses in mice. This lymphoma is theta 
169 
positive; that is, it bears an antigen marker attributed to lympho¬ 
cytes of thymic origin. Speculation prior to the experiment was that a 
T-cell malignancy might be characterized by heightened IgE production. 
Most manipulations that destroy T-cell function including radiation, J 
anti-thymocyte serum,and thymectomy,"^ generally predispose to in¬ 
creased IgE production. Increased IgE production clearly was not found 
in our experiments. Several explanations for this seem reasonable. 
First, although T-cells may be affected by L5178Y, their function, 

or at least their suppressor cell function, may be preserved. 
225 
Second, as T-cells are known to exert both a helper and a sup- 
223 pressor J effect over IgE production, perhaps affecting both 
equally allowed relatively normal IgE production. Third, the malig¬ 
nancy may have affected only a subset of all T-cells, leaving intact 
the subset vital for IgE response. Fourth, a tumor maintained in 
vivo or in vitro over a period of years may change its antigenic 
properties. Although we used the 'same9 tumor that other investiga¬ 
tors have found to be theta positive, only our own testing could verify 
this for our cell line, Finalljr, a transplanted malignancy might 
proliferate but leave the animal’s indigenous lymphocytes functioning 
relatively normally. 
112 
Acute lymphocytic leukemia may be derived from T-cells. In 
the few patients in whom it has been studied, IgE levels seem normal in 
this disease. The tumor most clearly bearing T-cell determinants in 
man is the Sezary cell. We are unaware of IgE levels having been mea¬ 
sured in tills disorder. 
Finally, the decreased. IgE levels in the mice given frozen tumor 
suggests a very speculative explanation. Viral infections, with measles 
62 l6 3 being one example under study, 1 D are known to affect immune respon¬ 
siveness and remission of allergic symptoms has been described following 
measles vaccine. ^ Perhaps the diminished IgE response and subsequent 
death of these animals was due to an activation of a latent virus from 
the frozen, lysed cells. 

-55- 
(C) Serum levels of IgE in childhood neoplasia 
If IgE confers a genetic selective advantage, this survival 
benefit must be present prior to child-bearing ago. We wished, 
therefore, to measure IgE levels in children with neoplasias. As 
children normally have low levels of IgE which rise gradually into 
adolescence, we needed a radioimmunoassay that was particularly sen¬ 
sitive to low serum values. As explained in Part II, such an assay 
was not commercially available at the time of this stu^y and so serum 
from children with a variety of tumors was collected and stored at 
-20°C for future investigation. 
Some limitations on the measurement of total serum IgE in cases 
of neoplasia deserve comment. First, neoplasms represent a variety of 
entities, each with a theoretical variety of causes. Even limiting 
study to childhood neoplasia, we had collected samples which included 
acute lymphocytic leukemia, acute undifferentiated leukemia, lympho¬ 
sarcoma, neuroblastoma, osteogenic sarcoma, and thyroid carcinoma. If 
total serum IgE is significant for any specific entity, this might be 
overlooked by considering all neoplasms together. Second, total serum 
IgE may be irrelevant as it might not reflect tumor-specific IgE. Normal 
levels of IgE vary widely so that a great deal of tumor-specific anti¬ 
body might be present but not be reflected in total serum levels. Fin¬ 
ally, finding abnormal levels of IgE would still leave the cause a mys¬ 
tery, Did low (or high) IgE predispose to malignancy or arise as a 
result? 

(D) Tumor-Specific IgE Responses in Kan 
Almost a decade before the discovery of IgE as a unique class of 
immunoglobulins, a report was published indicating that IgE could be 
involved in the antt-tumor immune response of some individuals. The 
work of GraceCurtis^ and co-workers showing that patients with 
cutaneous manifestations of malignancy had immediate wheal and flare 
reactions to their tumors established that IgE was involved, even 
though IgE was not known to be a separate antibody class at the time. 
Our studies designed to demonstrate that some individual do make 
an IgE response against tumors had two purposes. First, we merely 
wished to verify the previous reports. Second, if we could readily 
develop a method to determine if a given individual was making an IgE 
response, then the implications of this response could be system¬ 
atically evaluated. For example, what is the effect of IgE on the 
course and prognosis of the tumor? What characterizes the tumors and 
the individuals who tend to produce the IgE response? Does the presence 
of an IgE response suggest therapy? 
The same method available to Grace and Curtis, namely the P-K re¬ 
action, was not available to us. Current ethical standards would not 
permit the transfer of solubilized human tumors to volunteers. There¬ 
fore, two alternative methods to establish the presence of an IgE response 
were evaluated, immunofluorescence and histamine release. The results 
with the former are described; the latter method is currently being 
investigated. 
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Most of the studies involve breast carcinoma because 1) five 
74 
of Grace's patients had this disease,' 2) Black's data on skin 
windows shows that basophils are prognostically significant in breast 
cancer,and 3) the disease is common enough so that tissue was 
readily available. We were unable to obtain tissue on any patient 
who had a cutaneous sign of malignancy. 
Methods; 
Tissue- All tissue was obtained either from surgical pathology or 
directly from the operating room usually within sixty minutes of its 
removal and often in less time. Tissue from 21 patients was obtained. 
Malignant tiss^^e came from nine females with breast carcinoma and one 
with a breast sarcoma. Control tissue included sections from two re¬ 
duction raammoplasties, biopsies from five cases of fibrocystic dis¬ 
ease, breast tissue from a majre with gynecomastia, and a spleen free 
of tumor from a patient with Hodgkin’s disease. Tonsils and nasal 
polyps were obtained to provide positive controls. Immediately after 
its receipt, all tissues were frozen in liquid nitrogen and then 
stored at -90°C, Within a few weeks of its surgical removal, tissues 
were allowed to come to a temperature of -20°C and sectioned at a 
thickness of four to six microns with a cryostat. These sections were 
placed on microscope slides and stored at -90° C in sealed containers until 
ready for use, usually within a week or two. On one occasion, tissue 
from a patient with fibrocysiic disease was obtained directly from sur¬ 
gical pathology and immunofluorescence was performed without the inter¬ 
vening storage of tissue. 
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Antisera- Commercial antisera to human immunoglobulin G and E 
prepared in goats were purchased from Meloy Laboratories, Spring- 
field, Va. These antisera were fluoresceinated with a fluorescein 
to protein ratio of 3.3 ug/mg for the anti-IgE and 6.2 ug/mg for 
the anti-IgG, Fluoresceinated antisera to human IgA and to rat 
immunoglobulin produced in goats were given to us by Dr. Michael 
ICashgarian. These had been purchased from Hyland Laboratories. All 
antisera were diluted with saline at a ratio of 1:5 except for the 
anti-IgG which was diluted 1:10. 
Sera- Serum from the respective patients was obtained from the blood 
bank. Serum was diluted 1:10 with saline before use. 
Immunofluorescence- Both direct and indirect immunofluorescence studies 
were usually performed. For indirect immunofluorescence one step in the 
procedure must involve incubation of the tissue with serum prior to the 
incubation with antiserum. For direct immunofluorescence this step is 
omitted. The direct technique detects antibody on the surface of the 
cell, while the indirect procedure looks for antibody in the serum that 
has become attached to cellular antigen 
Slides were taken from the freezer at -90° C and allowed to come 
to room temperature before removing them from their sealed containers. 
Slides were then washed with agitation in phosphate buffered saline (PBS) 
for ten minutes. Slides were dried and placed over a moistened piece 
of filter paper. The tissue was then covered with the appropriate serum 
or antiserum. After a thirty minute incubation at 37° C slides were 
washed twice for ten minute periods in PBS while being shaken on a 
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platform. For direct immunofluorescence, slides were next dried, 
the tissue covered with a drop of phosphate buffered glycerine, and 
a coverslip put in place. For indirect studies, slides were subjected 
to a second incubation at 37°C, this time with appropriate antisera, 
and then two more ten minute washes were performed prior to being 
covered. Slides were viewed within hours of completion of the staining 
with a Zeiss microscope equipped with ultraviolet light. 
Histology- Hematoxylin and eosin (E&E) sections and phase contrast 
microscopy were performed with some of the sections in order to localize 
the areas of fluorescence. 
Results: 
Initial studies involved only the Keloy antisera to IgG and IgE. These 
studies indicated, that the sections from four of six patients with 
malignancy stained with both of the fluoresceinated antisera after 
direct and indirect immunofluorescence. Tissue from the five patients 
with fibrocystic disease and the two patients with reduction mammoplas¬ 
ties stained with anti-IgG consistently, but never significantly with 
anti-IgE. Both benign and malignant tissue stained occasionally with 
anti-IgE in areas of vascular smooth muscle. Such staining was not 
considered positive. 
With the help of Dr. Michael Ka'shgarian, H & E stains of the slides 
were prepared. Examining the slides under light and phase contrast 
microscopy verified that the immunofluorescence in the positive specimens 
was predominantly over the area of malignant cells. However, when the 
control of fluoresceinated anti-rat immunoglobulin was added to the 

procedure, this antiserum too stained the areas with malignant 
tissue in a pattern identical to that obtained with anti-IgE. 
Some of the tissues collected including the sarcomatous breast 
and the spleen from the paitent with Hodgkin's disease have not 
been sectioned but remain in storage in -90°C. Their ultimate use 
will depend upon the progress of further immunofluorescence studies. 
Discussion; 
Immunofluorescence as a technique for demonstrating a humoral 
118 
immune reaction to a tumor was first described by Klein et a|. in 
patients with Burkitt's lymphoma. "While immunofluorescence has been 
18 
used to locate IgE in such diverse studies as those on nasal polyps, 
03 q 70 
the thyroid in Graves' disease, J' the kidney in the nephrotic syndrome, 
!33 and peripheral blood lymphocytes in a variety of disease states,^*6?, 
± we are yn^are of any previous study that has used immuno¬ 
fluorescence to investigate the role of IgE in response to a solid tumor. 
Our initial results were extremely encouraging, but performance 
of adequate controls indicated that this enthusiasm was premature. The 
artifactual staining of tumor tissue may be due to a number of factors 
including necrosis of the cells despite our diligence in freezing the 
tissue as rapidly as possible. The malignant cells may be more sensi¬ 
tive to the experimental conditions and thus they attracted the anti-IgE 
while the benign tissue samples may have had less necrosis. Breast tissue 
does have significant local immunoglobulin production ^ and this 
might explain the staining for anti-IgG in all tissues, benign and 
malignant. Another possibility is that these malignant cells are especi- 
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ally cytophilic for proteins. 
Immunofluorescence studies not involving IgE have been performed 
188 
with breast carcinoma."0 However, these studies involved tumor cells 
that have been grown in culture. With such a system, one can more 
easily control the staining procedure and artifact by using a set 
number of cells for each trial. As human tumors including breast 
25? 
carcinoma tend to have common antigenic determinants, a single tumor 
groid.ng in culture could be used to test sera of numerous patients 
with the technique of indirect immunofluorescence. Such testing would 
assume that the common antigen(s) is the one recognised by IgE. While 
breast carcinoma is not considered one of the easier tumors to grow in 
culture, cells obtained from pleural effusions secondary to the tumor 
do grp® fairly readily in vitro. 
We are currently approaching the problem of demonstrating that 
some individuals produce tumor-specific IgE with the use of a histamine 
release assay. Basophils in high concentration can be found among the 
26/i leukocytes from blood sedimented with dextran or Ficoll-Hypaque, v If 
a paitent has produced IgE specific for his tumor, this IgE should have 
passively sensitized his own basophils. Adding solubilized tumor antigen 
to these leukocytes should cause the release of histamine as the cell 
degranulates. 
If human tumors do cause the release of histamine, the implications 
may relate to both pathogenesis and therapeutics. Histamine or other 
vasoactive substances released by IgE may be implicated in the cutaneous 
signs of some tumors. And substances that block or neutralize the pro- 
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ddcts of an IgE-antigen reaction would be logical pharmacologic 
agents to evaluate. 
Paradoxes in evaluating the putative IgE response to tumors 
are plentiful. The data on CBH suggests that the basophil can play 
a role in tumor rejection, while the present understanding of his¬ 
tamine’s effect on the immune response suggests that it should ham¬ 
per tumor rejection. Work with adjuvants like E. pertussis implies 
to some that a tumor-specific IgE response is beneficial, but re¬ 
ports on cutaneous manifestations of malignancy suggest that IgE 
may be -the culprit. IgE is elevated in Hodgkin's disease presumably 
secondary to depressed T-cell function, but lowered T-cell function 
is found often in malignancy and IgE levels are either normal or low. 
Is atopy related to the tendency to make a tumor-specific IgE response? 
Do skin signs appear in the absence of an IgE response? Does an IgE 
response occur in the absence of skin signs? Why should IgE be related 
to dermatologic disease? A histamine release assay is a reliable, 
reproducible technique that should greatly facilitate the answering 
of these questions. 
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SIMURY 
The possible role of IgE in response to neoplasia is reviewed with 
speculations offered about the possible implications of this res¬ 
ponse. Experimental efforts were divided bwtween basic research 
on IgE and studies directly involving tumors. Of the basic studies , 
A) the use of a solid phase radioimmunoassay (RIA) was perfected; 
B) evaluation of diurnal rhythms awaits commercial availability or 
a more sensitive, reproducible assay; and C) preliminary work on the 
ontogenetics of IgE suggests that its synthesis may be independent 
of the prior maturation of IgM bearing cells. Of the tumor-related 
studies, A) the demonstration in animals of IgE specific for tumor 
antigen has progressed so that its accomplishment should be attain¬ 
able; B) the studies on IgE responses to ovalbumin in tumor-bearing 
mice suggest that the tumor-bearing animals make antibody responses 
nearly comparable to controls even with the transplantion of a theta 
positive lymphoma; C) the work on IgE levels in childhood malignan¬ 
cies must await the aforementioned RIA; and D) studies now in pro¬ 
gress are attempting to demonstrate IgE responses to tumors in human 
subjects with the use of immunofluorescence and a histamine release 
assay. 
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